HOUSTON – Bracewell represented The University of Texas MD Anderson Cancer Center in connection with structuring its ownership interest in Immatics US, Inc. (Immatics US), which was originally formed by German-based Immatics Biotechnologies GmbH. Immatics US, which will be based in Houston, Texas, will focus on adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Immatics US has secured its first round of funding for $60 million, with more than $40 million committed by Immatic Biotechnologies Gmbh and $19.7 million by a recent award grant from the Cancer Prevention and Research Institute of Texas (CPRIT). In connection with its ownership interest in Immatics US and its significant clinical oncology and cell therapy expertise, MD Anderson has provided Immatics US with access to various technologies developed or in-licensed by MD Anderson in order to develop the optimal ACTs for the treatment of cancer.
Bracewell attorneys working on this transaction include:
Associates: Lytch Tornow